Welcome!

News Feed Item

Status Epilepticus Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Status Epilepticus Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280949/Status-Epilepticus-Global-Clinical-Trials-Review-H2-2014.html

Status Epilepticus Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Status Epilepticus Global Clinical Trials Review, H2, 2014" provides data on the Status Epilepticus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Status Epilepticus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Status Epilepticus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Status Epilepticus 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Status Epilepticus to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Status Epilepticus to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Status Epilepticus 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Status Epilepticus Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Sage Therapeutics 30
Clinical Trial Overview of Sage Therapeutics 30
Ligand Pharmaceuticals, Inc. 31
Clinical Trial Overview of Ligand Pharmaceuticals, Inc. 31
Mylan Inc. 32
Clinical Trial Overview of Mylan Inc. 32
Clinical Trial Overview of Top Institutes / Government 33
Assistance Publique - Hopitaux de Paris 33
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 33
Eunice Kennedy Shriver National Institute of Child Health and Human Development 34
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 34
Xuanwu Hospital Capital Medical University 35
Clinical Trial Overview of Xuanwu Hospital Capital Medical University 35
University of Malawi 36
Clinical Trial Overview of University of Malawi 36
Postgraduate Institute of Medical Education and Research 37
Clinical Trial Overview of Postgraduate Institute of Medical Education and Research 37
Shiraz University of Medical Sciences 38
Clinical Trial Overview of Shiraz University of Medical Sciences 38
University of Virginia 39
Clinical Trial Overview of University of Virginia 39
Hillel Yaffe Medical Center 40
Clinical Trial Overview of Hillel Yaffe Medical Center 40
All India Institute of Medical Sciences 41
Clinical Trial Overview of All India Institute of Medical Sciences 41
University of Michigan 42
Clinical Trial Overview of University of Michigan 42
Five Key Clinical Profiles 43
Appendix 67
Abbreviations 67
Definitions 67
Research Methodology 68
Secondary Research 68
About GlobalData 69
Contact Us 69
Disclaimer 69
Source 69

List of Tables

Status Epilepticus Therapeutics, Global, Clinical Trials by Region, 2014* 7
Status Epilepticus Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Status Epilepticus Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Status Epilepticus Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Status Epilepticus Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Status Epilepticus Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Status Epilepticus Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Status Epilepticus Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Status Epilepticus Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Status Epilepticus Therapeutics, Global, Withdrawn Clinical Trials, 2014* 24
Status Epilepticus Therapeutics, Global, Terminated Clinical Trials, 2014* 24
Status Epilepticus Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Status Epilepticus Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 26
Status Epilepticus Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Status Epilepticus Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Status Epilepticus Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Sage Therapeutics, 2014* 30
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Ligand Pharmaceuticals, Inc., 2014* 31
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Mylan Inc., 2014* 32
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 33
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 34
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Xuanwu Hospital Capital Medical University, 2014* 35
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Malawi, 2014* 36
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Postgraduate Institute of Medical Education and Research, 2014* 37
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Shiraz University of Medical Sciences, 2014* 38
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Virginia, 2014* 39
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Hillel Yaffe Medical Center, 2014* 40
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2014* 41
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014* 42

List of Figures

Status Epilepticus Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Status Epilepticus Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Status Epilepticus Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Status Epilepticus Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Status Epilepticus Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Status Epilepticus Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Status Epilepticus Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Status Epilepticus Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Status Epilepticus Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Status Epilepticus Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Status Epilepticus Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 26
Status Epilepticus Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Status Epilepticus Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Status Epilepticus Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
GlobalData Methodology 68


To order this report: Status Epilepticus Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280949/Status-Epilepticus-Global-Clinical-Trials-Review-H2-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that IoT Global Network has been named “Media Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. The IoT Global Network is a platform where you can connect with industry experts and network across the IoT community to build the successful IoT business of the future.
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...
When applications are hosted on servers, they produce immense quantities of logging data. Quality engineers should verify that apps are producing log data that is existent, correct, consumable, and complete. Otherwise, apps in production are not easily monitored, have issues that are difficult to detect, and cannot be corrected quickly. Tom Chavez presents the four steps that quality engineers should include in every test plan for apps that produce log output or other machine data. Learn the ste...
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Enterprises are universally struggling to understand where the new tools and methodologies of DevOps fit into their organizations, and are universally making the same mistakes. These mistakes are not unavoidable, and in fact, avoiding them gifts an organization with sustained competitive advantage, just like it did for Japanese Manufacturing Post WWII.
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term.
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
Machine learning provides predictive models which a business can apply in countless ways to better understand its customers and operations. Since machine learning was first developed with flat, tabular data in mind, it is still not widely understood: when does it make sense to use graph databases and machine learning in combination? This talk tackles the question from two ends: classifying predictive analytics methods and assessing graph database attributes. It also examines the ongoing lifecycl...
Daniel Jones is CTO of EngineerBetter, helping enterprises deliver value faster. Previously he was an IT consultant, indie video games developer, head of web development in the finance sector, and an award-winning martial artist. Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams.
CloudEXPO New York 2018, colocated with DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
Digital transformation has increased the pace of business creating a productivity divide between the technology haves and have nots. Managing financial information on spreadsheets and piecing together insight from numerous disconnected systems is no longer an option. Rapid market changes and aggressive competition are motivating business leaders to reevaluate legacy technology investments in search of modern technologies to achieve greater agility, reduced costs and organizational efficiencies. ...
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.